Agios Pharmaceuticals, Inc.

Quick facts

Phase 3 pipeline

• AG-348 · Hematology
  AG-348 activates pyruvate kinase R (PKR), an enzyme that increases ATP production in red blood cells to improve their survival and reduce hemolysis.
• Placebo Matching Mitapivat · Hematology
  Mitapivat activates pyruvate kinase R (PKR), an enzyme that increases ATP production in red blood cells to improve their survival and function.

Phase 1 pipeline

• [13C2,15N3]-tebapivat
• [13C315N3]AG-881
• [13C6]AG-348
• [14C]-AG-120
• [14C]-tebapivat
• AG-181
• AG-236
• AG-348 Sequence A
• AG-348 Sequence B
• AG-881 · Oncology
  Tet methylcytosine dioxygenase 2 (TET2) inhibitor
• AG-946
• AG120 · Oncology
  Inhibits mutant IDH1 enzyme
• AG221 · Oncology
  IDH2 inhibitor
• AG881 Formulation 1
• Mitapivat coated granules
• Mitapivat tablet
• Mitapivat tablets

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

• Agios Pharmaceuticals, Inc. portfolio CI brief
• Agios Pharmaceuticals, Inc. pipeline updates RSS